30 October 2023
30 October 2023
Mainstream popularity is driving the acceptance of AI, yet lack of talent, regulatory uncertainty, and unknown impact may be halting the adoption.
Following positive interim data, Novartis adds atrasentan to the 2024 accelerated approval list alongside iptacopan.
AC Immune’s a-syn PET tracer, ACI-12589, showed specific and reproducible retention patterns in patients with multiple system atrophy.
All patients in the high-dose and low-dose centanafadine arms of these studies showed improvements versus placebo.
Findings showed that mazdutide offered a placebo-adjusted mean body weight loss of 18.6% from baseline.
The spin-off will see Sanofi follow in the footsteps of fellow pharma giants Johnson & Johnson, Pfizer, and Novartis.
Progression-free survival is the primary objective of the trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
